TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study - 06/09/17
Summary |
Background |
In patients with heavily treated metastatic colorectal cancer, TAS-102—a combination of trifluridine and tipiracil—has shown a significant overall survival benefit compared with placebo. In preclinical models, TAS-102 plus bevacizumab has shown enhanced activity against colorectal cancer xenografts compared with that for either drug alone. In this phase 1/2 study, we assessed the activity and safety of TAS-102 plus bevacizumab.
Methods |
We did this investigator-initiated, open-label, single-arm, multicentre, phase 1/2 trial of TAS-102 plus bevacizumab in four cancer centres in Japan. Eligible patients were aged 20 years or older; had histologically confirmed unresectable, metastatic colorectal adenocarcinoma; were refractory or intolerant to fluoropyrimidine, irinotecan, oxaliplatin, anti-VEGF therapy, and anti-EGFR therapy (for tumours with wild-type KRAS); and had no previous treatment with regorafenib. Patients had to have an Eastern Cooperative Oncology Group performance status of 0 or 1. Using a dose de-escalation design in phase 1, the recommended phase 2 dose (RP2D) was determined for TAS-102 (35 mg/m2 given orally twice daily on days 1–5 and 8–12 in a 28-day cycle for level 1) plus bevacizumab (5 mg/kg, administered by intravenous infusion for 30 min every 2 weeks). In phase 2, patients received the RP2D. The primary endpoint was centrally assessed progression-free survival at 16 weeks, analysed in the first 21 patients to be enrolled and treated with the RP2D who had at least one imaging assessment. This study is completed and registered with the University Hospital Medical Information Network, number UMIN000012883.
Findings |
Between Feb 25, 2014, and July 23, 2014, we enrolled 25 patients with metastatic colorectal cancer: six patients in phase 1 and 19 patients in phase 2. The six patients who received TAS-102 at level 1 experienced no dose-limiting toxicities and this was deemed the RP2D. Nine of 21 patients who received the RP2D did not have a centrally assessed progression event; 16-week progression-free survival was 42·9% (80% CI 27·8–59·0). The most common grade 3 or worse adverse events as assessed in all 25 patients were neutropenia (18 [72%] patients), leucopenia (11 [44%]), anaemia (four [16%]), febrile neutropenia (four [16%]), and thrombocytopenia (three [12%]). Treatment-related serious adverse events were reported in three (12%) patients. No treatment-related deaths occurred.
Interpretation |
TAS-102 plus bevacizumab has promising activity with manageable safety, suggesting that this combination might become a potential treatment option for patients with metastatic colorectal cancer in a refractory setting.
Funding |
Taiho Pharmaceutical.
Le texte complet de cet article est disponible en PDF.Plan
Vol 18 - N° 9
P. 1172-1181 - septembre 2017 Retour au numéro
Article précédent
- First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials
- Harpreet S Wasan, Peter Gibbs, Navesh K Sharma, Julien Taieb, Volker Heinemann, Jens Ricke, Marc Peeters, Michael Findlay, Andrew Weaver, Jamie Mills, Charles Wilson, Richard Adams, Anne Francis, Joanna Moschandreas, Pradeep S Virdee, Peter Dutton, Sharon Love, Val Gebski, Alastair Gray, FOXFIRE trial investigators, SIRFLOX trial investigators, FOXFIRE-Global trial investigators, Guy van Hazel, Ricky A Sharma, Richard Adams, Andrew Bateman, Claire Blesing, Ewan Brown, Ian Chau, Sebastian Cummins, David Cunningham, Stephen Falk, Maher Hadaki, Marcia Hall, Tamas Hickish, Joanne Hornbuckle, Fiona Lofts, Sarah Lowndes, Astrid Mayer, Matthew Metcalfe, Gary Middleton, Jamie Mills, Amir Montazeri, Rebecca Muirhead, Andreas Polychronis, Colin Purcell, Paul Ross, Ricky A Sharma, Liz Sherwin, David Smith, Rubin Soomal, Daniel Swinson, Axel Walther, Harpreet Wasan, Andrew Weaver, Charles Wilson, Greg Wilson, Pradip Amin, Bruna Angelelli, Jacques Balosso, Alex Beny, Daniel Bloomgarden, Evelyn Boucher, Michael Brown, Harald-Robert Bruch, James Bui, Matthew Burge, Giuseppe Cardaci, James Carlisle, Seungjean Chai, Yi-Jen Chen, Patrick Chevallier, Michael Chuong, Stephen Clarke, Andrew Coveler, Michael Craninx, Thierry Delanoit, Amélie Deleporte, Paul Eliadis, Francis Facchini, Thomas Ferguson, Michel Ferrante, Michael Findlay, Gary Frenette, Jacob Frick, Vinod Ganju, Michael Garofalo, Karen Geboes, Gerald Gehbauer, Benjamin George, Ravit Geva, Peter Gibbs, Michael Gordon, Kate Gregory, Seza Gulec, James Hannigan, Guy van Hazel, Norman Heching, Volker Heinemann, Thomas Helmberger, Alain Hendlisz, Koen Hendrickx, Matthew Holtzman, Richard Isaacs, Christopher Jackson, Philip James, Adeel Kaiser, Chris Karapetis, Andreas Kaubisch, Yon-Dschun Ko, Hendrik Kröning, Frank Lammert, Winston Liauw, Steven Limentani, Samy Louafi, Marc de Man, Jeffrey Margolis, Robert Martin, Andrea Martoni, Gavin Marx, Marco Matos, Els Monsaert, Veerle Moons, Louise Nott, Arnd Nusch, Anne O’Donnell, Howard Ozer, Siddarth Padia, Nick Pavlakis, Marc Peeters, David Perez, Stefan Pluntke, Marc Polus, Alex Powell, Marc Pracht, Timothy Price, David Ransom, Christine Rebischung, Jens Ricke, Karsten Ridwelski, Jorge Riera-Knorrenschild, Hanno Riess, William Rilling, Bridget Robinson, Javier Rodríguez, Federico Sanchez, Tilmann Sauerbruch, Michael Savin, Klemens Scheidhauer, Elyse Schneiderman, Grant Seeger, Eva Segelov, Einat Shaham Schmueli, Adi Shani, Jenny Shannon, Navesh Sharma, Stephen Shibata, Nimit Singhal, Denis Smith, Randall Smith, Salomon Stemmer, Oliver Stötzer, Andrew Strickland, Julien Taieb, Klaus Tatsch, Eric Terrebonne, Thomas Tichler, Ursula Vehling-Kaiser, Ruth Vera-Garcia, Thomas Vogl, Euan Walpole, Eric Wang, Samuel Whiting, Ido Wolf, Steven Ades, Morteza Aghmesheh, Bruna Angelelli, Miklos Auber, Hubert Ayala, Alex Beny, Daniel Bloomgarden, Patrick Boland, Eveline Bouche, Charles Bowers, Christoph Bremer, James Bui, Mathew Burge, James Carlisle, Ana Ruiz Casado, Seungjean Chai, Michael Chuong, Prasad Cooray, Martin Crain, Maike De Wit, Kyran Dowling, Aurelie Durand, Francis Facchini, Sandrine Faivre, Kynan Feeney, Tom Ferguson, Aurelie Ferru, Michael Findlay, Maria Fragoso, Gary Frenette, Jacob Frick, Vinod Ganju, Ravit Geva, Peter Gibbs, Cristina Granetto, Pascal Hammel, Guy van Hazel, Norman Heching, Alain Hendlisz, Koen Hendrickx, Matthew Holtzman, Richard Issacs, Renuka Iyer, Christopher Jackson, Adeel Kaiser, Andreas Kaubisch, Yeul Hong Kim, Hendrik Kröning, Jin Tung Liang, Lionel Lim, Steven Limentani, Jin Hwang Liu, Samy Louafi, Marc de Man, Gianluca Masi, Marco Matos, Els Monsaert, Stefania Mosconi, Louise Nott, Gianmauro Numico, Anne O’Donnell, Marc Peeters, Marc Polus, Marc Pracht, Lynn Ratner, Christine Rebischung, Han Sae-Won, Federico Sanchez, Adi Shani, Navesh Sharma, Madhu Singh, Nimit Singhal, Denis Smith, Patricia Stoltzfus, Andrew Strickland, Julien Taieb, Iain Tan, Eric Terrebonne, Thomas Tichler, Antonio Trogu, Craig Underhill, Ruth Vera-Garcia, Euan Walpole, Eric Wang, Mark Westcott
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
- Michael J Overman, Ray McDermott, Joseph L Leach, Sara Lonardi, Heinz-Josef Lenz, Michael A Morse, Jayesh Desai, Andrew Hill, Michael Axelson, Rebecca A Moss, Monica V Goldberg, Z Alexander Cao, Jean-Marie Ledeine, Gregory A Maglinte, Scott Kopetz, Thierry André
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?